MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QOD	MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QOD	MEL-JUSO Belvarafenib 200mg QD Cobi 20mg QOD	MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QOD	MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QD	MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QD	MEL-JUSO Belvarafenib 200mg QD Cobi 20mg QD	MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QD	MEL-JUSO Belvarafenib 50mg QD Cobi 40mg QD	MEL-JUSO Belvarafenib 100mg BID Cobi 40mg QD	MEL-JUSO Belvarafenib 200mg QD Cobi 40mg QD	MEL-JUSO Belvarafenib 400m Cobi 40mg Q	BID	MEL-JUSO Belvarafenib 50mg QD Cobi 60mg QD	MEL-JUSO Belvarafenib 100mg BID Cobi 60mg QD	MEL-JUSO Belvarafenib 200mg QD Cobi 60mg QD	В	MEL-JUSO delvarafenib 400mg BID Cobi 60mg QD
Relative Viability 1.00 0.75 0.50 0.25 0.00	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3	RelativeViability 1.00 0.75 0.50 0.25 0.00	Dility We relative Viability Relative Viability 1.00 0.75 0.50 0.25 0.00 -3	RelativeViability 1.00 0.75 0.50 0.25 0.00	-23333333 -	iability No Va qui juming 00 1,000 75 0,50 25 0,50 30 0,25 30 0,25	7/ability	MEKi_Cobimetinib uM -3 -	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3	RelativeViability 1.00 0.75 0.50 0.25 0.00 -3	Relative Viability 1.00 Nn 1.00	Relative Viability		Relative Viability 1.00 0.75 0.50 0.25 0.00 -3	Relative Viability 1.00 1.00 0.75 0.50 0.25 0.00 -3 -	Relative Viability	RelativeViability 1.00 0.75 0.50 0.25 0.00
-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QD	panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QD	-3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 40mg QD	-4 -3 panRAFi_Belvarafei MEL-JUS Belvarafenib 400 Cobi 40mg (ng BID	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 60mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 60mg QD	-4 -3 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 60mg QD		-3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 60mg QD
HSA Excess 0.6 0.3 0.0 -0.3 -0.6	HSA Excess 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	HSA Excess 0.6 0.3 0.0 -0.3 -0.6	Dess No.	HSA Excess 0.6 0.0 0.0 -0.3 -0.6 WE WITH THE PROPERTY OF THE P	-1- -2- -3-	Excess 0.6	Excess 0.6	The state of the s	HSA Excess 0.6 0.0 0.0 1.3 -0.6 -3	HSA Excess 0.6 0.0 0.0 0.0 0.3 -0.6 -3	HSA Excess 0.6 0.0 0.0 0.0 1.3 0.0 -0.6 -3 -	HSA Excess 0.6 0.0 0.0 -0.3 -0.6 -3 -		HSA Excess 0.6 0.0 0.0 0.0 1.3 -0.6 -3	HSA Excess 0.6 0.0 0.0 0.0 -0.3 -0.6 -3 -	HSA Excess 0.6 0.0 0.0 -0.3 White in the second secon	HSA Excess 0.6 0.3 0.0 -0.3 -0.6
-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 40mg QD		nib uM ag BID D	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 60mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 60mg QD	-4 -3 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 60mg QD		panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 60mg QD
Bliss Excess 0.50 0.25 0.00 -0.25 -0.50 -0.50	Bliss Excess 9.50 0.50 0.00 1.25 0.00	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50 Page 14 Page 14	Ceess Wn -2 - 0.50 Wn -2 - 0.25 Wn -2 - 0.25 Wy -2 - 0.25 Wy -2 - 0.25 Wy -2 - 0.50 Wn -2 - 0.50	Bliss Excess -0.50 0.00 0.00 -0.25 -0.50 -0.50 -0.85 -0.85 -0.80	Bliss Exc -2 -3 panRAFi. Belvaratenib uM	Excess 0.50 Mg -2 - 0.25 -0.50 -3 -3 -2 -2 -2 -3 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2	Excess 0.50 May 2-2 0.25 0.00 0.50 0.25 0.00 -0.25 -0.50 -0.50 -0.50	WEKI_Copinetinib um	Bliss Excess 0.50 0.50 0.00 0.25 0.00 0.25 0.00 -0.25 -0.50 -3 panRAFi, Belvarafenib uM	Bliss Excess 0.50 0.00 -0.25 -0.50 -0.50 -0.50 -0.73 PanRAFi. Belvarafenib uM	Bliss Excess 0.50 Which is a series of the	Bliss Excess 0.50 0.00 -0.25 -0.50 -0.50 -0.50 -0.50 -0.50 -0.50	1-4 -3 -2 panRAFi_Belvarafenib uM	Bliss Excess 0.50 0.00 0.00 0.00 0.05 -0.25 -0.50 -0.50 -3 panRAFi, Belvarafenib uM	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50 -0.50 -3 panRAFi, Belvarafenib uM	Bliss Excess 0.50 0.00 0.00 0.25 0.25 0.00 -0.25 -0.50 -3 -4	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50
SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QOD	SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QOD	SK-MEL-2 Belvarafenib 200mg QD Cobi 20mg QOD	SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QOD	SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QD	SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QD	SK-MEL-2 Belvarafenib 200mg QD Cobi 20mg QD	SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QD	SK-MEL-2 Belvarafenib 50mg QD Cobi 40mg QD	SK-MEL-2 Belvarafenib 100mg BID Cobi 40mg QD	SK-MEL-2 Belvarafenib 200mg QD Cobi 40mg QD	SK-MEL-2 Belvarafenib 400m Cobi 40mg Q	BID -1 -	SK-MEL-2 Belvarafenib 50mg QD Cobi 60mg QD	SK-MEL-2 Belvarafenib 100mg BID Cobi 60mg QD	SK-MEL-2 Belvarafenib 200mg QD Cobi 60mg QD	В	SK-MEL-2 delvarafenib 400mg BID Cobi 60mg QD
RelativeViability -2 0.9 0.6 0.3 0.0	Relative Viability O.9 O.6 O.0 O.0 O.0 O.0 O.0 O.0 O.0	RelativeViability 0.9 0.6 0.3 0.0	bility Winding in the control of th	Relative Viability 0.9 0.6 0.3 0.0	RelativeViab 0.9 0.6 0.3 0.0	Relative Via	WERRITOR OF THE PROPERTY OF TH	MEKi_Cobimetinib uM	Relative Viability 0.9 0.6 0.3 0.0 -3	RelativeViability 0.9 0.6 0.3 0.0 -3	RelativeViability Wn qqueling QO Visit Vi	Relative Viability O.9 O.6 O.3 O.0 -3		Relative Viability O.9 O.6 O.3 O.0 -3	Relative Viability 0.9 0.6 0.3 0.0 -3	Relative Viability Wn quipper	Relative Viability 0.9 0.6 0.3 0.0
-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD Cobi 20mg QOD	-43 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD Cobi 40mg QD	-4 -3 panRAFi_Belvarafer SK-MEL- Belvarafenib 400 Cobi 40mg 6	-4	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 60mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 60mg QD	-4 -4 -3 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD Cobi 60mg QD		-3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID Cobi 60mg QD
HSA Excess -1- 0.4 0.0 -0.4	HSA Excess Wn quipunquip	HSA Excess 0.4 0.0 -0.4	Cesss White The Company of the Compa	HSA Excess O.4 O.0 -0.4 VMEXICODIUM	-1- -2- -3-	Excess 0.4 0.0 -0.4 -3 HSA EX HS	Excess 0.4 0.0 -0.4 -3 HSA Excess 0.4 0.0 -0.4	MEKi_Cobimetinib uM -3-	HSA Excess When the second se	HSA Excess W -2 - 0.4 0.0 -0.4 -0.4 -3 -	HSA Excess Who -2 - 0.0 0.0 in the second of the secon	HSA Excess Wind a state of the		HSA Excess Who -2 - 0.4	HSA Excess Who diminished the second of the	HSA Excess Who -2 - 0.4 Who will be seen to be seen	HSA Excess
panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD	panRAFi_Belvaraf SK-MEL- Belvarafenih 400	nib uM	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg OD		panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID
Bliss Excess 0.5 0.0 0.0 -0.5 Page 14 - 4 - 3 - 3 - 2 Page 14 - 4 - 3 - 3 Page 14 - 4 - 4 - 3 Page 14 - 4 - 4 - 3 Page 15 - 4 - 4 - 3 Page 15 - 4 - 4 - 4 - 3 Page 15 - 4 - 4 - 4 - 3 Page 15 - 4 - 4 - 4 - 4 - 3 Page 15 - 4 - 4 - 4 - 4 - 4 Page 15 - 4 - 4 - 4 - 4 Page 15 - 4 - 4 - 4 - 4 Page 15 - 4 - 4 - 4 - 4 Page 15 - 4 Page	Bliss Excess Wn quipauligo O D D D D D D D D D D D D D D D D D D	Bliss Excess 0.5 0.0 0.0 -0.5	Cobi 20mg QOD The state of the	Bliss Excess 0.5 0.0 0.0 -0.5 Page 14 -3 -2 panRAFi_Belvarafenib uM	Bliss Exc -2 -3 panRAFi_Belvarafenib uM	Excess 0.5 0.0 0.0 -0.5 -0.5 Display a series of the	Excess 0.5 0.0 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5	We with the state of the state	Bliss Excess What a display in the second of the second o	Bliss Excess O.5 O.0 O.0 O.5 A A A A A A A A A A A A A	Bliss Excess W -2 - 0.5 0.0 0.0 -0.5 A -3 panRAFi_Belvaraf	Bliss Excess Who distributed by the state of the state o	-4 -3 panRAFi_Belvarafenib uM	Bliss Excess Vin question in a contract of the contract of th	Bliss Excess 0.0 0.0 -0.5 WE will be the control of the contro	Bliss Excess Wn -2 0.5 0.0 -0.5 -3 -4	Bliss Excess 0.5 0.0 0.0 -0.5 panRAFi_Belvarafenib uM
Belvaratenib 50mg QD	Belvaratenio 100mg BiD	Beivaratenib 200mg QD	Beivaratenid 400mg BiD	Beivaratenio 50mg QD	Belvaratenib 100mg BID	Beivaratenib 200mg QD	Beivaratenib 400mg BiD	Belvaratenib 50mg QD	Beivaratenib 100mg BiD	Beivaratenib 200mg QD	Beivaratenib 400m	BID	Beivaratenib 50mg QD	Belvaratenib 100mg BiD	Beivaratenio 200mg QD	В	selvaratenib 400mg BID
Relative Viability 1.00 0.75 0.50 0.25 0.00	Relative Viability In the property of the pro	RelativeViability 1.00 0.75 0.50 0.25 0.00	Cobi 20mg QOD The state of the	RelativeViability 1.00 0.75 0.50 0.25 0.00 7 panRAFi_Belvarafenib uM	RelativeViab 1.00 0.75 0.50 0.25 0.00	Relative Via 1.00	Relative Viability Triability Triability	WEK! Copimetinib mm -2	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3 panRAFi_Belvarafenib uM	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3 panRAFi_Belvarafenib uM	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3 panRAFi_Belvarafer	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3	-3 panRAFi_Belvarafenib uM	RelativeViability 1.00 0.75 0.50 0.25 0.00 -3 panRAFi_Belvarafenib uM	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3 panRAFi_Belvarafenib uM	Relative Viability 1.00 0.75 0.50 0.25 0.00 -3	Relative Viability 1.00 0.75 0.50 0.25 0.00
-1 -	-1 -		-1-		-1-	-1 -	-1 -	-1 -	-1 -	-1 -	-1 -	-1 -		-1 -	-1-	-1 -	
HSA Excess 0.6 0.3 0.0 0.0 -0.3 -0.6	HSA Excess 0.6 0.0 0.0 0.0 1.3 1.4 1.4 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	HSA Excess 0.6 0.3 0.0 -0.3 -0.6	HSA Excess Mon quineurigo Dyya A Japan RAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID	HSA Excess 0.6 0.3 0.0 -0.3 -0.6 -0.6	-2 -3 -3 -2	EXCESS 0.6	Excess 0.6 0.6 0.6 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	What is a second of the second	HSA Excess 0.6 0.0 0.0 -0.3 -0.6 -3 -4 -4 -3 -2	HSA Excess 0.6 0.0 0.0 0.0 1.3 -0.6 -3 -3 -2	HSA Excess 0.6 0.0 0.0 0.0 1.3 -4 -4 -3	HSA Excess 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	-4 -3 -2	HSA Excess 0.6 0.0 0.0 0.0 0.0 -0.3 -0.6 -3 -3 -2	HSA Excess 0.6 0.0 0.0 0.0 -0.3 Where the second control is a second control in the second control in th	HSA Excess 0.6 0.0 0.0 0.0 1.3 -0.6 -3 -4	HSA Excess 0.6 0.3 0.0 -0.3 -0.6
panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 200mg QD Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 200mg QD Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 200mg QD Cobi 40mg QD	panRAFi_Belvaraf SK-MEL-3 Belvarafenib 400 Cobi 40mg (nib uM ng BID D	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 60mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 60mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 200mg QD Cobi 60mg QD		panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 60mg QD
Bliss Excess 0.50 0.50 0.25 0.25 0.00 -0.25 -0.50	Bliss Excess 0.50 0.50 0.00 0.00 0.00 0.00 0.00 0.	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50 Page 14 Page 15 Page 15	Dess 1.50	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50 -0.80	Bliss Exc O D A P P P P P P P P P P P P	Excess 0.50	Excess 0.50	WEK! Copiumetruip WEK! Copiume	Bliss Excess 0.50	Bliss Excess 0.50	Bliss Excess 0.50 0.00 -0.25 -0.25 -0.50 -3 panRAFi_Belvaraf	Bliss Excess 0.50 0.00 -0.25 -0.50 -0.50 -3	1-4 -3 -2 panRAFi_Belvarafenib uM	Bliss Excess 0.50 0.00 0.00 0.05 -0.25 -0.50 -0.50 -3 panRAFi_Belvarafenib uM	Bliss Excess 0.50 W -2 -0.25 Use windows -0.50 -0.50 -3 -3 -3 -3 panRAFi_Belvarafenib uM	Bliss Excess 0.50 0.00 0.00 -0.25 -0.50 -0.50 -0.50 -0.50	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50